Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer

• Status: Terminated
• Trial end date: 2013-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the highest dose of Vinorelbine and Pazopanib that can be given together without causing severe side effects. Also, this study will evaluate what effects (good and bad) that the treatment has on patients and their cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwestern University
• Collaborator: Robert H. Lurie Cancer Center
• Treatments: Vinblastine; Vinorelbine

Criteria

Inclusion Criteria:

• Age > 18 years

• Patients must have diagnosis of breast cancer or non small cell lung cancer

• Patients must have evaluable disease

• Women of childbearing potential and sexually active males must commit to the use of effective contraception while on study.

• Patients must have given signed, informed consent prior to registration on study.

Exclusion Criteria:

• Patients must not be pregnant and/or lactating.

• Patients must not be receiving any other investigational agents.

• No prior exposure to vinorelbine or other VEGF inhibitors as treatment for metastatic disease

• Patients must not have received prior therapy (including radiation, surgery, and/or chemotherapy) within 30 days

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or vinorelbine.

• Patients cannot have received more than 2 prior chemotherapy regimens for lung cancer or 3 prior chemotherapy regimens for breast cancer. This criterion can be discussed further with the study doctor.

• Must not have uncontrolled illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmic, psychiatric illness/social situations that would limit compliance with study requirements.